Danish Pharmacovigilance Update, 16 February 2012

In this issue of Danish Pharmacovigilance Update:

• Risk of overdose with methotrexate in the treatment of rheumatoid arthritis and psoriasis (front page)
• Gilenya (fingolimod) – intensified monitoring of heart rate and blood pressure after first dose (front page)
• Newest data on the safety of methylphenidate (Ritalin etc.) in ADHD therapy (pp 2-3)
• Risk of thromboembolism or death after discontinuation of anticoagulant therapy in patients with atrial fibrillation (pp 4-5)
• Risk of venous thromboembolism from the use of 4th generation contraceptive pills (Yasmin® etc.) (p 6)
• New report from the Danish Medicines Agency about the use of contraceptive pills and risk of thrombosis (pp 6-7)
• Gilenya and macular oedema (p 7)
• Haemorrhagic disease in a newborn whose mother was treated with valproate during pregnancy (p 8)
• Study of the linkage between urine-derived fertility products and Creutzfeldt-Jakob (p 9)
• The Danish Medicines Agency has drawn up a new report on pregnancy and adverse reactions from antidepressants (p 10)
• New mobile app for checking medicines (p 10)